Kitasato Daiichi Sankyo Vaccine Co., Ltd. Sustainability Profile
Kitasato Daiichi Sankyo Vaccine Co., Ltd., a prominent player in the biopharmaceutical industry, is headquartered in Japan. Established in 2005, the company has rapidly evolved, focusing on the research, development, and production of innovative vaccines. With a strong operational presence in Asia and beyond, Kitasato Daiichi Sankyo is dedicated to addressing global health challenges through its advanced vaccine solutions. The company’s core offerings include a range of vaccines designed to combat infectious diseases, distinguished by their cutting-edge technology and rigorous safety standards. Kitasato Daiichi Sankyo has achieved notable milestones, including collaborations with international health organisations, positioning itself as a trusted name in vaccine development. With a commitment to quality and innovation, the company continues to play a vital role in enhancing public health worldwide.
DitchCarbon Score
How does Kitasato Daiichi Sankyo Vaccine Co., Ltd.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Kitasato Daiichi Sankyo Vaccine Co., Ltd.'s score of 74 is higher than 84% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Kitasato Daiichi Sankyo Vaccine Co., Ltd., headquartered in Japan, currently does not report specific carbon emissions data, as no emissions figures are available. The company is a current subsidiary of Daiichi Sankyo Company, Limited, which may influence its climate commitments and initiatives. While Kitasato Daiichi Sankyo Vaccine Co., Ltd. has not set specific reduction targets or disclosed its own climate pledges, it inherits sustainability initiatives from its parent company, Daiichi Sankyo Company, Limited. This includes participation in the Science Based Targets initiative (SBTi), the Carbon Disclosure Project (CDP), and the RE100 initiative, all of which aim to enhance corporate accountability in reducing carbon emissions and transitioning to renewable energy sources. As a subsidiary, Kitasato Daiichi Sankyo Vaccine Co., Ltd. aligns with the broader climate strategies of Daiichi Sankyo Company, Limited, which are designed to mitigate environmental impact and promote sustainability within the pharmaceutical and vaccine sectors.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Scope 1 | 182,519,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 2 | 290,715,000 | 000,000,000 | 000,000,000 | 000,000,000 | - | 000,000,000 | 000,000,000 | 000,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 3 | 5,704,000 | - | - | - | - | - | - | - | - | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 |
How Carbon Intensive is Kitasato Daiichi Sankyo Vaccine Co., Ltd.'s Industry?
How Carbon Intensive is Kitasato Daiichi Sankyo Vaccine Co., Ltd.'s Location?
Kitasato Daiichi Sankyo Vaccine Co., Ltd.'s Scope 3 Categories Breakdown
Kitasato Daiichi Sankyo Vaccine Co., Ltd.'s Scope 3 emissions, which decreased by 6% last year and increased significantly since 2011, demonstrating supply chain emissions tracking. Nearly all of their carbon footprint comes from suppliers and value chain emissions, representing nearly all emissions under the GHG Protocol, with "Purchased Goods and Services" being the largest emissions source at 85% of Scope 3 emissions.
Top Scope 3 Categories
Kitasato Daiichi Sankyo Vaccine Co., Ltd.'s Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Kitasato Daiichi Sankyo Vaccine Co., Ltd. has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
